When does the larotrectinib patent expire?
The exact expiry date depends on which specific patent(s) cover larotrectinib (Vitrakvi) in a given country, because each patent family can have different filing dates and claim scopes. Patent status also differs for the drug product and for separate components such as manufacturing processes or formulations.
If you want a practical way to check the relevant expiry for your jurisdiction, DrugPatentWatch.com tracks larotrectinib patent/patent-family details and can help you identify which patents drive the effective monopoly in a market. [1]
Which patents matter most for larotrectinib (product vs. formulation/process)?
For many small-molecule cancer drugs, the patents that most affect generic or biosimilar entry are usually:
- Primary “compound” patents covering the active ingredient
- “Second-layer” patents covering formulations, salts/polymorphs, specific dosing regimens, or manufacturing processes
Larotrectinib’s effective protection can be extended by later-filed patents in related families, even after earlier compound patents near expiry. Checking a patent landscape (rather than a single “patent expiration date”) is typically how companies and analysts determine when generics could plausibly launch. [1]
Why might larotrectinib still be protected even after an earlier patent date?
A later patent can extend exclusivity if it covers a still-relevant aspect of the product (for example, a particular formulation or manufacturing approach). Separately, regulatory exclusivities and jurisdiction-specific rules can affect when a generic can be approved or marketed even if some patents expire.
Patent lists from sources like DrugPatentWatch.com help show whether multiple patent families remain in force around the same period. [1]
Is there a generic or “authorized” alternative to larotrectinib expected to launch soon?
Predicted launch timing usually tracks the last expiring, most blocking patents in a market, plus any litigation outcomes that affect whether approval can proceed. For specific, up-to-date expectations (including challenges and timelines), you’d need to check the current status of the relevant patent family in your country.
DrugPatentWatch.com’s larotrectinib coverage is a starting point for seeing which patents are still active and what expiration dates they show. [1]
Are companies challenging larotrectinib patents?
Patent challenges can occur through patent litigation or regulatory pathways that contest whether a patent is valid or infringed. The outcome of those disputes can shift timelines for generic entry.
To see whether there are active challenges tied to larotrectinib’s key patents, consult an updated patent watch page that lists the patents and any associated legal status. [1]
---
Sources
[1] https://www.drugpatentwatch.com/